| 5/28/2013 | BKCVHY | Moody's might upgrade Bausch
|
| 3/25/2013 | BKCVHY | S&P lifts Bausch & Lomb view to positive
|
| 4/19/2012 | BKCVHY | Moody's rates Bausch & Lomb facilities B1
|
| 4/19/2012 | BKCVHY | S&P: Bausch & Lomb loan B+
|
| 3/28/2012 | BKCVHY | Moody's: Deal is negative for Bausch & Lomb
|
| 9/9/2011 | BKCVHY | Moody's: No changes for Bausch & Lomb
|
| 4/13/2010 | BKCVHY | Moody's ups Bausch & Lomb outlook to stable
|
| 4/1/2009 | BKCVHY | Moody's: Bausch & Lomb outlook negative
|
| 10/26/2007 | CVHY | Bausch & Lomb completes tender for 6.95%, 5.9%, 6.56%, 7 1/8% notes, convertible floaters
|
| 10/5/2007 | BKCVHY | Moody's rates Bausch & Lomb loans B1, notes Caa1
|
| 10/4/2007 | BKCVHY | S&P cuts Bausch & Lomb, rates loans BB-, notes B-
|
| 9/21/2007 | BKCVHY | S&P keeps Bausch & Lomb on watch
|
| 9/19/2007 | CVHY | Bausch & Lomb tenders for six series of notes, convertibles
|
| 7/10/2007 | BKCVHY | S&P: Bausch & Lomb remains on watch
|
| 7/10/2007 | CVHY | Bausch & Lomb to tender for notes if Warburg Pincus merger proceeds
|
| 7/6/2007 | CV | Market Commentary: All eyes on Bausch & Lomb, Advanced Medical Optics; Huntsman up again; Hilton flattens
|
| 6/26/2007 | CV | Market Commentary: Gannett jumbo deal, GSI issue on tap; Huntsman surges on merger; Amgen slides; Medtronic rises
|
| 6/8/2007 | CV | Market Commentary: Bausch & Lomb unmoved by fading hopes of rival offer; Amgen, Intel, Ford recover; market still cautious
|
| 5/29/2007 | CV | Market Commentary: Archstone trims hedges; Advanced Medical, Bausch & Lomb fall on recall; NII, Luminent plans deals
|
| 5/25/2007 | CV | Market Commentary: GM roars ahead; Archstone-Smith gains, Bausch & Lomb up, Advanced Medical quiet on takeover talk
|
| 5/24/2007 | CV | Market Commentary: Bausch & Lomb quiet on bidding event, Advanced Medical Optics slides; GM slightly higher in gray
|
| 5/17/2007 | CV | Market Commentary: Countrywide improves on debut; Bausch & Lomb calms down from buyout fever; Micron gains in gray
|
| 5/16/2007 | CV | Market Commentary: Bausch & Lomb gains on buyout; CV Therapeutics keeps rising; Countrywide, Micron launch giant deals
|
| 5/16/2007 | BKCVHY | S&P lowers Bausch & Lomb
|
| 5/16/2007 | BKCVHY | Moody's keeps Bausch & Lomb on review
|
| 5/16/2007 | BKCVHY | Fitch keeps Bausch & Lomb on watch
|
| 4/23/2007 | CV | Market Commentary: MedImmune surges on buyout; Bausch & Lomb climbs on rumors; AMD, Charming Shoppes launch deals
|
| 3/6/2007 | CV | Market Commentary: Bausch & Lomb gains; DexCom quiet on debut; Barnes absent in gray; Cypress, Developers launch deals
|
| 2/7/2007 | CV | Bausch & Lomb seeks extends solicitation for notes due 2023
|
| 2/2/2007 | BKCVHY | Moody's cuts Bausch & Lomb to junk
|
| 1/31/2007 | CV | Bausch & Lomb seeks consents to amend notes including convertibles due 2023
|
| 11/10/2006 | BKBTCV | S&P: Bausch & Lomb unaffected
|
| 10/16/2006 | CV | Market Commentary: Open Solutions soars on buyout; Bausch and Lomb, Wyeth slip on rate fears; SanDisk gains on outlook
|
| 9/29/2006 | BTCV | Bausch & Lomb obtains needed consents for six notes series
|
| 9/28/2006 | BTCV | Bausch & Lomb prolongs consent solicitation for 7 1/8% debentures, receives consents for other notes
|
| 8/8/2006 | CV | Market Commentary: McData gains with offer; Teva rides earnings boost; Scottish Re firms as put stays; Charter slips on loss
|
| 5/22/2006 | CV | Bausch gets required consents for 7.125% debentures, other notes, convertibles
|
| 5/17/2006 | CV | Bausch extends consent solicitation for 7.125% debentures, gets consents for other notes, convertibles
|
| 5/15/2006 | CV | Market Commentary: Bausch and Lomb gains on product recall; FEI prices $100 million deal within talk
|
| 5/12/2006 | BTCV | Fitch downgrades Bausch & Lomb
|
| 5/4/2006 | CV | Market Commentary: Bausch and Lomb up dollar-neutral on debt tenders; JDS Uniphase falls outright on poor guidance
|
| 5/3/2006 | CV | Bausch & Lomb to solicit consents for convertibles
|
| 4/24/2006 | CV | Market Commentary: Bausch and Lomb, Schlumberger get analysts' thumbs up; Halliburton, Medtronic shrug off reports
|
| 4/21/2006 | CV | Market Commentary: Mercury Interactive gains on waiver consent offer; Vitesse marked lower on delayed filings
|
| 4/13/2006 | CV | Market Commentary: Medtronic gains dollar-neutral on debut; Bausch and Lomb rebounds before product pulled
|
| 4/12/2006 | BTCVHY | Fitch puts Bausch & Lomb on negative watch
|
| 4/12/2006 | BTCVHY | Moody's keeps Bausch & Lomb on review for downgrade
|
| 4/12/2006 | CV | Market Commentary: Bausch and Lomb firms against falling stock; Cypress rebounds as Synaptics flattens; Rentech debut quiet
|
| 4/11/2006 | BTCVHY | S&P cuts Bausch & Lomb outlook to negative
|
| 4/11/2006 | CV | Market Commentary: Bausch and Lomb wider on product scare; Synaptics gains on iPod rumors; Medtronic plans $4 billion deal
|
| 3/23/2006 | BTCVHY | Moody's may cut Bausch & Lomb
|
| 3/17/2006 | BTCV | S&P: Bausch & Lomb unchanged
|
| 5/10/2005 | CV | Moody's pulls Bausch & Lomb from junk
|
| 4/8/2005 | CV | S&P raises Bausch & Lomb
|
| 2/17/2005 | CV | Fitch rates Bausch & Lomb BBB
|
| 2/7/2005 | CV | Moody's: Bausch & Lomb up to positive
|
| 12/17/2004 | CV | S&P rates Bausch & Lomb convertibles BBB-
|
| 12/15/2004 | CV | Bausch & Lomb exchanges 98.6% of convertibles
|
| 11/15/2004 | CV | S&P: Bausch & Lomb unaffected
|
| 11/15/2004 | CV | Bausch & Lomb starts exchange for convertibles
|
| 9/24/2004 | CV | Market Commentary: Calpine new issue trade seen awkward; Dobson off on buy; PMA Capital exchange seen
|
| 7/2/2004 | CV | S&P: Bausch & Lomb unaffected
|
| 5/28/2004 | CV | S&P: Bausch & Lomb stable
|
| 1/29/2004 | CV | Market Commentary: Wyeth, Sallie Mae, Lockheed floaters see demand; hedgies hurt by premium contractions
|
| 7/30/2003 | CV | Market Commentary: ExpressJet in holding pattern, waiting on Continental signal; three other new deals emerge
|
| 7/29/2003 | CV | New Issue: Bausch & Lomb $140 million cash-to-zero convertible pays 6-mo Libor+50 bps, up 50%
|
| 7/29/2003 | CV | S&P rates Bausch & Lomb at BBB-
|
| 7/29/2003 | CV | Market Commentary: ExpressJet soars in gray market, as do most of new issues in play; Nextel Partners, Dynegy emerge
|
| 7/28/2003 | CV | Bausch & Lomb $140 million cash-to-zero floaters talked at 6-mo Libor plus 15-65 bps, up 48-52%
|
| 7/28/2003 | CV | Market Commentary: Dynegy seen launching smaller convert early Tuesday; seven other deals launched Monday
|
